<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=26988"><dc:title>Inflammatory biomarkers as predictors of prognosis in patients after transcatheter aortic valve implantation</dc:title><dc:creator>Vitez,	Luka	(Avtor)
	</dc:creator><dc:creator>Mihailović,	Peter Marko	(Avtor)
	</dc:creator><dc:creator>Božič Mijovski,	Mojca	(Avtor)
	</dc:creator><dc:creator>Jug,	Borut	(Avtor)
	</dc:creator><dc:creator>Bunc,	Matjaž	(Avtor)
	</dc:creator><dc:subject>systemic inflammatory response syndrome</dc:subject><dc:subject>SIRS</dc:subject><dc:subject>transcatheter aortic valve implantation</dc:subject><dc:subject>high sensitivity CRP</dc:subject><dc:subject>hs-CRP</dc:subject><dc:subject>interferon gamma</dc:subject><dc:subject>IFN-γ</dc:subject><dc:subject>inflammatory biomarkers</dc:subject><dc:description>Background: The expanding role of transcatheter aortic valve implantation (TAVI) highlights the need to identify factors influencing long-term outcomes. Systemic inflammatory response syndrome (SIRS) is a frequent post-procedural event that may adversely affect prognosis. Measurement of inflammatory biomarkers may improve the understanding of underlying mechanisms and refine patient risk stratification.Methods: This single-center, prospective cohort study, enrolled 62 consecutive patients undergoing TAVI, who were followed for up to 5 years. Blood samples were collected before TAVI, at 24 h and 3–6 months post-procedure. Changes in biomarker levels, predictors of SIRS, and inflammatory predictors of long-term outcomes were analyzed.Results: SIRS developed in 45% of patients. Significant temporal changes were observed in hs-CRP, TNF-α, sST2/IL-33, IL-10, and IL-2 levels, irrespective of baseline or procedural characteristics. The development of SIRS was associated with a higher risk of all-cause mortality or unplanned hospitalization at 5 years (HR 3.07, 95% CI 1.57–6.00; p = 0.001). Baseline hs-CRP (HR 1.21, 95% CI 1.09-1.35; p &lt; 0.001) and IFN-γ (HR 1.22; 95% CI 1.09–1.36; p &lt; 0.001) levels were predictive of adverse outcomes. In multivariable Cox analysis, these associations remained, though findings should be interpreted cautiously given the limited sample size.Conclusions: SIRS is a common post-TAVI phenomenon and may be linked to long-term outcomes. Elevated pre-procedural hs-CRP and IFN-γ levels were associated with higher risk for adverse events, suggesting they may serve as exploratory biomarkers for risk stratification in this population.</dc:description><dc:date>2026</dc:date><dc:date>2026-01-28 11:25:18</dc:date><dc:type>Neznano</dc:type><dc:identifier>26988</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
